Which phases have Neurocept clinical trials completed for Alzheimer's?

1. Why this question can’t be answered from the supplied reporting

I searched the supplied documents for “Neurocept” or any trial record tied to that sponsor and found no mention; the publicly available overviews and news pieces in the provided set instead catalogue the 2025 Alzheimer’s pipeline as a whole and highlight specific companies (e.g., Novo Nordisk, J&J, Eisai/Biogen) and numbers of trials and drugs — but not Neurocept (available sources do not mention Neurocept; ^[1]; ^[2]; p1_s3).

2. What the supplied pipeline reviews do tell us about Alzheimer’s trials in 2025

Two curated, peer‑reviewed pipeline overviews report the AD drug development landscape as of January 1, 2025: 182 active trials testing 138 novel drugs, with 48 Phase 3, 86 Phase 2, and 48 Phase 1 trials. These reviews count trials by phase and note that repurposed agents make up roughly one‑third of the pipeline and that biomarkers figure prominently in eligibility and outcomes ^{[1] [2]}.

3. Recent high‑profile late‑stage trial news that provides context

Major industry players drew attention in late 2025: Novo Nordisk halted or reported negative results from two large semaglutide (Rybelsus) Alzheimer’s trials that together randomized 3,808 patients, a setback that underlines how high‑risk, late‑stage AD trials remain. Reuters and The New York Times reported that the Rybelsus studies failed to slow cognitive decline in thousands of people with mild disease ^{[3] [4]}. These accounts demonstrate how quickly the late‑phase landscape can shift and help explain why independent confirmation (trial registries or sponsor statements) is crucial when identifying which sponsor has reached which phase ^{[3] [4]}.

4. How to check Neurocept’s completed phases using primary records

Because the supplied sources don’t mention Neurocept, the authoritative way to answer your original question is to consult primary registries and sponsor disclosures: ClinicalTrials.gov entries (search by sponsor “Neurocept” or by the specific drug name), company press releases, and peer‑reviewed publications that report trial phase and status. The pipeline reviews emphasize that trials must be registered on ClinicalTrials.gov and use that registry as the foundation for phase counts, underscoring the registry’s role as the definitive record for phase completions ^{[1] [2]}.

5. Conflicting viewpoints and reporting caveats in the supplied material

The supplied reporting shows two useful tensions: (a) curated academic pipeline reports provide a snapshot of where trials stood on a specific index date and can miss rapid sponsor moves after that date; and (b) journalism (Reuters, NYT) provides timely coverage of high‑profile trial outcomes but focuses on headline programs and may not catalogue every small or private sponsor’s activity. Together, they explain why a company like Neurocept could be absent from these sources even if it has trials — the pipeline reviews and news items prioritize registered, visible trials and major sponsors ^{[1] [2] [3]}.

6. Practical next steps I recommend

• Look up Neurocept on ClinicalTrials.gov to see registered trials, phase designations, start/completion dates, and results postings ^[1].
• Check Neurocept’s own website and press releases for trial announcements and phase‑completion statements (not present in the provided sources).
• If you want, share any Neurocept trial identifiers or drug names you already have and I will cross‑check them against the supplied sources and say whether they appear (available sources do not mention Neurocept; ^[1]; p1_s9).

Limitations: my analysis is constrained to the documents you provided; those sources do not mention Neurocept, so I cannot state which phases Neurocept has completed without consulting registries or other reporting beyond this set (available sources do not mention Neurocept; ^[1]; p1_s9).